Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
351 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (3)

Medical Condition

  • Show all (1900)
  • Addiction (16)
  • Allergy, Asthma, & Immunology (12)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (28)
  • Blood Disorders (38)
  • Bone & Muscle (10)
  • Cancer (726)
  • Child Development (4)
  • COVID-19 (Coronavirus) (37)
  • Critical Illness (1)
  • Dental (2)
  • Developmental Disorders (2)
  • Diabetes (22)
  • Ear, Nose and Throat (11)
  • Endocrine & Metabolic Disease (13)
    • Cushing's Disease (3)
    • (-) Growth Hormone Deficiency (1)
  • Eye (8)
  • Gastrointestinal and Digestive Diseases (22)
  • Hair and Skin Disorders (2)
  • Headaches (5)
  • Healthy Volunteers (175)
  • Heart Disease (128)
  • Infectious Disease (48)
  • Insomnia (2)
  • Kidney Disease (12)
  • Liver Disease (48)
    • Cirrhosis of the Liver (5)
    • (-) Hepatic Encephalopathy (2)
    • Hepatitis (11)
    • Liver Failure (2)
    • NASH (3)
  • Lung Disease (32)
  • Meniere's Disease (1)
  • Neurological Disorders (174)
  • Nutrition (4)
  • Obesity (9)
  • Obstetrics & Gynecology (51)
  • Pain Management (1)
  • Pediatrics (104)
  • Psychiatric Disorders (65)
  • Rehabilitation (8)
  • Stroke (7)
  • Surgery (7)
  • Transplant (51)
  • Urology (4)
  • Vascular Conditions (9)
Displaying 1 - 3 of 3

Study for patients with with hepatic encephalopathy using drug, rifaximin

Condition: Liver Disease / Hepatic Encephalopathy
Investigator: Robert Brown, MD, MPH
Status: Closed
The purpose of this study is to compare the time to onset of an episode of overt HE, in subjects with previously demonstrated overt HE after treatment with rifaximin 550 mg BID and lactulose, or rifaximin 550 mg BID. Subjects will be screened to confirm eligibility into the study. Once confirmed, subjects will begin the treatment phase and will be randomly…
Read More

A study for adults with growth hormone deficiency using study drug NNC0195-0092

Condition: Endocrine & Metabolic Disease / Growth Hormone Deficiency
Investigator: Pamela Freda, MD
Status: Closed
The purpose of this study is to investigate how well weekly injections of the growth hormone drug NNC0195-0092 works in adults with growth hormone deficiency. Growth hormone deficiency is a disorder that involves the pituitary gland (a small gland located at the base of the brain). The gland produces growth hormone and other hormones (chemical messengers of…
Read More

A study to assess the documentation of Hepatic Encephalopathy in clinical practice

Condition: Liver Disease / Hepatic Encephalopathy
Investigator: Robert Brown, MD, MPH
Status: Closed
The purpose of this study is to find out how doctors describe hepatic encephalopathy episodes in patients medical records in the course of their regular practice. The aim of the study is simply to collect information from their medical records about how their episodes of overt hepatic encephalopathy are described. There is nothing that will be required of…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science